65,437 trials
Depressive Disorder, Major
Primary: Change in Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF) From Baseline up to Day 56 — 39.3; 9.6; 15.1; 19.0 Units on a scale
Actinic Keratoses
Primary: Histological Lesion Clearance — 38.5; 69.2 percentage of complete histological clea
Thyroid Carcinoma
Primary: Tumor Response Rate to LBH589. — 13; 0 participants
Acute Coronary Syndrome
Primary: Platelet-thrombus Formation in an ex Vivo Model of Thrombosis — 56.3; 35.2 percent change
Osteoarthritis, Hip
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 Subscore (Walking Pain) Over 26 Weeks — -2.26; -2.19 units on a scale…
Pulmonary Embolism
Primary: Technical Success — 89 participants
Breast Cancer
Primary: Ipsilateral Breast Tumor Recurrence — 1.4; 1.5 percentage of participants
Pain
Primary: Change in the Pain Intensity Score (0-10 NRS) From Visit 1 (Baseline) to 6weeks After Treatment. — -2.32; -2.75 Scores on a scale — p=0.2658
Multiple Actinic Keratoses
Primary: Histological Lesion Clearance — 61.5; 38.5 percentage of complete clearance — p=0.375
Hemorrhage
Primary: Hemostasis at the Target Bleeding Site (TBS) at 4-minutes Following Randomization — 48; 24 participants with hemostatic success — p=<.0001
Hodgkin's Lymphoma
Primary: Number of Participants With Adverse Events — 26; 11 Participants
Colorectal Cancer
Primary: Disease-Free Survival (Time to Event) — 25 months
Healthy Volunteer
Primary: Total Dialysate Clearance for Automated Peritoneal Dialysis (CLDAPD) of Oseltamivir and Oseltamivir Carboxylate for 75 mg Dose — NA; NA; 0.183; 0.230 Litre (L)/hour (h)
Coronary Artery Disease
Primary: MLD SB Diameter — 08.; 1.0; 2.3; 2.2 mm
Diabetes Mellitus, Type 2
Primary: Percentage of Participants With First Occurrence of Macro-vascular Event or Death — 58; 60.3 percentage of participants — p=0.3444